Antagonism of δ2-Opioid Receptors by Naltrindole-5′-isothiocyanate Attenuates Heroin Self-Administration but Not Antinociception in Rats1

Abstract

δ-Opioid receptors have been implicated in reinforcement processes and antagonists are available that produce long-lasting and selective antagonism of δ-opioid receptors in vivo. This experiment assessed the contribution of δ-opioid receptors to the antinociceptive and reinforcing properties of heroin. The effects of the irreversible δ-antagonist naltrindole-5′-isothiocyanate (5′-NTII) were evaluated on heroin self-administration and hot-plate antinociception in rats. 5′-NTII (10 nmol i.c.v.) shifted the dose-response curve for heroin self-administration downward, increasing the A50 values on the ascending and descending limbs by approximately 0.5 log units and decreasing the maximum by 33%. 5′-NTII (40 nmol i.c.v.) shifted both limbs of the heroin self-administration dose-effect curve 1.2 log units to the right and decreased the maximum by 90%. Heroin self-administration gradually returned to baseline levels over 7 or 17 days after administration of 10 or 40 nmol 5′-NTII, respectively. 5′-NTII (40 nmol i.c.v.) decreased the self-administration of 0.17 mg/infusion cocaine by 40% while having no effect on responding maintained by 0.33 or 0.67 mg/infusion. 5′-NTII attenuated the antinociceptive effects of deltorphin (δ2) in a dose-dependent manner while having no effect on antinociception elicited after i.c.v. administration of [d-Pen2,d-Pen5]-enkephalin (δ1) or [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (μ). In addition, the antinociceptive effects of heroin were not significantly affected by 5′-NTII (40 nmol i.c.v.). Therefore, 5′-NTII can attenuate the reinforcing effects of heroin at doses that do not affect its antinociceptive effects. Long-acting δ2-opioid antagonists may be beneficial in the treatment of heroin dependence or as adjuncts to reduce the abuse liability of opioid analgesics.

Footnotes

  • Send reprint requests to: Dr. Thomas J. Martin, Ph.D., Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1803. E-mail: tjmartin{at}wfubmc.edu

  • 1 This study was supported by the National Institute on Drug Abuse of the National Institutes of Health through Grants DA-00247 (to T.J.M.), DA-06284 (to F.P.), DA-08657 (to F.P.), DA-01999 (to J.E.S.), DA-06634 (to J.E.S.), and DA-12489 (to J.E.S.). F.P. is the recipient of a Research Scientist Development Award (KO2 DA-00185). J.E.S. is the recipient of a Senior Scientist Development Award (KO5 DA-00114).

  • Abbreviations:
    5′-NTII
    naltrindole-5′-isothiocyanate
    DPDPE
    [d-Pen2,d-Pen5]-enkephalin
    HP
    hot plate
    DAMGO
    [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
    FR
    fixed ratio
    DMSO
    dimethyl sulfoxide
    β-FNA
    β-funaltrexamine
    • Received November 16, 1999.
    • Accepted May 19, 2000.
« Previous | Next Article »Table of Contents